The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer

Hu, Xiaoge; Lei, Xiangxiang; Guo, Jinhui; Fu, Wen; Sun, Wen; Lu, Qiliang; Su, Wei; Xu, Qiuran; Tu, Kangsheng

doi:10.3389/fonc.2022.927640

Cited by 3 publications

(2 citation statements)

References 183 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three RNA-seq datasets GSE16561 (n = 63) 53 , GSE102541 (n = 9) 54 , and GSE140275 55 (n = 6) were downloaded from the Gene Expression Omnibus (GEO) database ( https://www.ncbi.nlm.nih.gov/gds/ ). GSE16561 was used as the training set which included 39 cases of IS samples and 24 of normal samples.…”

Section: Methodsmentioning

confidence: 99%

Identification of significant m6A regulators and immune microenvironment characterization in ischemic stroke

Zhao,

Song,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The role of m6A modification in the regulation of the immune microenvironment (IME) of ischemic stroke (IS) is barely known. Thus, we aim to investigate the impact of m6A modification on the IME of IS and its diagnostic value in IS. We comprehensively assessed the m6A modification patterns, the relationship between these modification patterns and the characteristics of the IME. The m6A modification patterns of individual IS sample were quantified by m6Ascore. The performance of m6A phenotype-related genes as potential biomarkers was evaluated by the area under the receiver operating characteristic curve. Experimental validation was also performed by qRT-PCR. Six dysregulated m6A regulators were identified and a classification model consisting of four key m6A regulators (METLL3, RBMX, RBM15B, YTDHF3) could distinguish IS and healthy control samples well. METTL3 and YTHDF3 are closely related to circulating neutrophil abundance. Two distinct m6A modification patterns were determined which differed in immunocyte abundance. We also identified six m6A phenotype-related genes (APOBEC3A, PTMA, FCGR3A, LOC440926, LOC649946, and FTH1L11), and further explored their biological function. Among them, APOBEC3A, FCGR3A, and FTH1L11 were positively associated with neutrophil abundance. APOBEC3A and FCGR3A were stable diagnostic m6A-associated genes in both the discovery and validation cohorts. This study reveals that m6A modification plays a non-negligible role in the formation of a diversified and complex IME in IS. The m6A phenotype-related genes could be diagnostic biomarkers of IS.

show abstract

Section: Methodsmentioning

confidence: 99%

Identification of significant m6A regulators and immune microenvironment characterization in ischemic stroke

Zhao,

Song,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Abnormal m6A modification of lncRNA is currently found in PC tissues and cell lines (Fig. 3 ) [ 137 , 138 ]. Chen et al found that METTL14-modified LncRNA LIFR-AS1 promotes the progression of PC.…”

Section: Functions Of Lncrna-rna Modification In Different Types Of C...mentioning

confidence: 99%

Emerging role of RNA modification and long noncoding RNA interaction in cancer

Yang,

Tang,

Min

et al. 2024

Cancer Gene Ther

View full text Add to dashboard Cite

RNA modification, especially N6-methyladenosine, 5-methylcytosine, and N7-methylguanosine methylation, participates in the occurrence and progression of cancer through multiple pathways. The function and expression of these epigenetic regulators have gradually become a hot topic in cancer research. Mutation and regulation of noncoding RNA, especially lncRNA, play a major role in cancer. Generally, lncRNAs exert tumor-suppressive or oncogenic functions and its dysregulation can promote tumor occurrence and metastasis. In this review, we summarize N6-methyladenosine, 5-methylcytosine, and N7-methylguanosine modifications in lncRNAs. Furthermore, we discuss the relationship between epigenetic RNA modification and lncRNA interaction and cancer progression in various cancers. Therefore, this review gives a comprehensive understanding of the mechanisms by which RNA modification affects the progression of various cancers by regulating lncRNAs, which may shed new light on cancer research and provide new insights into cancer therapy.

show abstract

Identification of key regulatory factors for m6A in myasthenia gravis and characteristics of the immune characteristics

Wu,

Cai,

Jiao

et al. 2024

Preprint

View full text Add to dashboard Cite

Myasthenia gravis (MG), a rare autoimmune disorder, presents a complex pathogenesis involving various immune molecules. The modification of N6-methyladenosine (m6A) regulates diverse immune metabolic and immunopathological processes; however, its role in MG remains unclear. We downloaded dataset GSE85452 from the GEO database to identify differentially expressed genes regulated by m6A. The Random Forest (RF) method was utilized to identify pivotal regulatory genes associated with m6A modification. Subsequently, a prognostic model was crafted and confirmed using this gene set. Patients with MG were stratified according to the expression levels of these key regulatory genes. Additionally, MG-specific immune signatures were delineated by examining immune cell infiltration patterns and their correlations. Further functional annotation, protein-protein interaction mapping, and molecular docking analyses were performed on these immune biomarkers, leading to the discovery of three genes that exhibited significant differential expression within the dataset: RBM15, CBLL1, and YTHDF1.The random forest algorithm confirmed these as key regulatory genes of m6A in MG, validated by constructing a clinical prediction model. Based on key regulatory gene expression, we divided MG patients into two groups, revealing two distinct m6A modification patterns with varying immune cell abundances. We also discovered 61 genes associated with the m6A phenotype and conducted an in-depth exploration of their biological roles. RBM15, CBLL1, and YTHDF1 were found positively correlated with CD56dim natural killer cells, natural killer T cells, and type 1 helper T cells. These genes were stable diagnostic m6A-related markers in both discovery and validation cohorts. Our findings suggest RBM15, CBLL1, and YTHDF1 as immune markers for MG. Further analysis of these genes may elucidate their roles in the immune microenvironment of MG.

show abstract

The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer

Cited by 3 publications

References 183 publications

Identification of significant m6A regulators and immune microenvironment characterization in ischemic stroke

Identification of significant m6A regulators and immune microenvironment characterization in ischemic stroke

Emerging role of RNA modification and long noncoding RNA interaction in cancer

Identification of key regulatory factors for m6A in myasthenia gravis and characteristics of the immune characteristics

Contact Info

Product

Resources

About